The METSSAR trial investigates a new dosing schedule for #selinexor in soft tissue sarcoma patients. The split-dose approach shows promising safety and tolerability, with no grade ≥ 3 adverse events reported. link.springer.com/article/10…
98
A multicenter study from Japan shows that combining baseline NLR and ΔNLR can help identify NSCLC patients who may benefit most from chemoimmunotherapy, providing valuable prognostic insights. link.springer.com/article/10… #openaccess #immunotherapy #NSCLC
75
Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of #Lenvatinib Clinical Trials: A Systematic Review link.springer.com/article/10…
80
Efficacy and Safety of Docetaxel plus #Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients link.springer.com/article/10… #NSCLC
53
Impact of AML1/ETO Fusion on the Efficacy of #Venetoclax Plus Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia link.springer.com/article/10… #AML #openaccess
38
#Inotuzumab in Older Patients with Newly Diagnosed Acute Lymphoblastic Leukemia—A #Podcast link.springer.com/article/10… #ALL #openaccess
35
A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G link.springer.com/article/10… #mCRC #openccess
31
EGFR and ERBB2 Exon 20 Insertion Mutations in Chinese Non-small Cell Lung Cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation link.springer.com/article/10…
45
Comparison of Adverse Events Between PARP Inhibitors in Patients with Epithelial #OvarianCancer: A Nationwide Propensity Score Matched Cohort Study link.springer.com/article/10…
27
Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World Data link.springer.com/article/10… #openaccess
25
Survival Benefit of Myeloablative Therapy with Autologous Stem Cell Transplantation in High-Risk #Neuroblastoma: A Systematic Literature Review link.springer.com/article/10… #openaccess
27
DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic #Melanoma link.springer.com/article/10… #immunotherapy #openaccess
28
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab link.springer.com/article/10… #immunotherapy #BTC
Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of #Immunotherapy link.springer.com/article/10… #mRCC #openaccess
39
#Lenvatinib Versus #Atezolizumab Plus Bevacizumab in the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis of Real-World Studies link.springer.com/article/10… #HCC #immunotherapy
41
#Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Nationwide Population-Based Study (THNS-2021-08) link.springer.com/article/10… #HNSCC
36
Prognostic Impact of HER2-Low and HER2-Zero in Resectable Breast Cancer with Different Hormone Receptor Status: A Landmark Analysis of Real-World Data from the National Cancer Center of China link.springer.com/article/10…
36
Safety and Efficacy of #Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma link.springer.com/article/10… #HCC
75
Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer link.springer.com/article/10… #mCRC
91
Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea link.springer.com/article/10…
44



















